QIAGEN N.V. reported net sales of $547,869 thousand and net income of $105,659 thousand for the three months ended September 30, 2026, compared with $532,583 thousand and $130,043 thousand for the three months ended September 30, 2025.
QGEN · Qiagen N.V.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 50%
- Last earnings
- Nov 4, 2026
- Price history
- Jan 2020 to Nov 2026
Up next
Latest documents
QIAGEN reported Q3 2026 net sales of $548 million, up 3% and 3% at constant exchange rates. Adjusted diluted EPS reached $0.65, but it suspended its 2026 outlook and withdrew guidance while the EQT Private Equity acquisition remains pending.
Crown NL Bidco B.V., a wholly owned subsidiary of Crown NL Midco B.V., plans a tender offer to acquire all QIAGEN N.V. ordinary shares at €46.50 per share in cash under a Business Combination Agreement dated October 21, 2026. The tender offer has not yet commenced and will be made under German law, pursuant to an offer document approved by BaFin.
Qiagen N.V. reported a Business Combination Agreement dated October 21, 2026, under which Crown NL Bidco B.V. plans a tender offer for all issued ordinary shares at €46.50 per share in cash, without interest. The tender offer has not yet commenced and is subject to BaFin clearance and the agreement's conditions.
Crown NL Bidco B.V. decided on 21 October 2026 to make a voluntary cash public takeover offer of €46.50 per QIAGEN share, a 40.3% premium to the €33.15 XETRA closing price on 8 July 2026. The QIAGEN boards agreed to fully support and recommend the offer, with closing expected mid 2027 subject to a minimum acceptance threshold of 50% of outstanding share capital plus one share.
Metrics snapshot
Useful current figures from the complete screener profile.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
QGEN
this stock
Qiagen N.V.
|
$10.25B | +10.4% | +5.7% | — | 3.1% |
|
TMO
Thermo Fisher Scientific Inc.
|
$255.19B | +18.9% | +14.5% | 36.3 | 1.3% |
|
DHR
Danaher Corp
|
$160.10B | -0.6% | +8.5% | 37.2 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$54.33B | +1.9% | +10.4% | 46.5 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$49.43B | +28.9% | +6.4% | 34.5 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 6, 2026
- This year
- 19
QIAGEN reported Q3 2026 net sales of $548 million, up 3% and 3% at constant exchange rates. Adjusted diluted EPS reached $0.65, but it suspended its 2026 outlook and withdrew guidance while the EQT Private Equity acquisition remains pending.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| QGEN | -0.9% | -1.2% | +37.2% | -1.2% | +10.4% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +4.5% | +5.1% | +42.8% | +4.1% | +5.4% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.